---
title: "Mizuho Securities Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294905895.md"
description: "Mizuho Securities analyst Uy Ear reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD) with a $36.00 price target, while shares closed at $27.15. The broader market consensus is a Moderate Buy with an average target of $33.21. Additionally, H.C. Wainwright maintained a Buy rating with a $37.00 target in a July 30 report."
datetime: "2026-08-05T03:35:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294905895.md)
  - [en](https://longbridge.com/en/news/294905895.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294905895.md)
generator: "portal-rs"
---

# Mizuho Securities Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)

Mizuho Securities analyst Uy Ear reiterated a Buy rating on ACADIA Pharmaceuticals yesterday and set a price target of $36.00. The company’s shares closed yesterday at $27.15.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Ear covers the Healthcare sector, focusing on stocks such as Alkermes, Arcutis Biotherapeutics, and ACADIA Pharmaceuticals. According to TipRanks, Ear has an average return of 5.7% and a 42.38% success rate on recommended stocks. 

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $33.21 average price target, implying a 22.32% upside from current levels. In a report released on July 30, H.C. Wainwright also maintained a Buy rating on the stock with a $37.00 price target.

### Related Stocks

- [ACAD.US](https://longbridge.com/en/quote/ACAD.US.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)
- [ALKS.US](https://longbridge.com/en/quote/ALKS.US.md)
- [ARQT.US](https://longbridge.com/en/quote/ARQT.US.md)

## Related News & Research

- [GSA Capital Partners LLP Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD](https://longbridge.com/en/news/296084900.md)
- [ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data](https://longbridge.com/en/news/295699458.md)
- [Mark Schneyer Sells 5,849 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock](https://longbridge.com/en/news/295283718.md)
- [Acadia Pharmaceuticals CFO Mark C. Schneyer disposes of 25,141 common shares worth $730,047.52](https://longbridge.com/en/news/295281807.md)
- [Acadia Pharmaceuticals Q2 revenue rises on DAYBUE STIX demand, lifts 2026 outlook](https://longbridge.com/en/news/294866410.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**